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Digital	Orphans:	Data	closure	and	openness	in	
patient-powered	networks	
	
ABSTRACT	In	this	paper,	we	discuss	an	issue	linked	to	data-sharing	regimes	in	patient-powered,	social-media-based	networks,	namely	that	much	of	the	data	that	patient	users	share	are	not	used	to	research	scientific	issues	or	the	patient	voice.	This	is	not	a	trivial	issue,	as	participation	in	these	networks	is	linked	to	openness	in	data	sharing,	which	would	benefits	fellow	patients	and	contributes	to	the	public	good	more	generally.	Patient-powered	research	networks	are	often	framed	as	disrupting	research	agendas	and	the	industry.	However,	when	data	that	patients	share	are	not	accessible	for	research,	their	epistemic	potential	is	denied.	The	problem	is	linked	to	the	business	models	of	the	organisations	managing	these	networks:	models	centred	on	controlling	patient	data	tend	to	close	networks	with	regard	to	data	use.	The	constraint	on	research	is	at	odds	with	the	ideals	of	a	sharing,	open	and	supportive	epistemic	community	that	networks’	own	narratives	evoke.	This	kind	of	failure	can	create	peculiar	scenarios,	such	as	the	emergence	of	the	‘digital	orphans’	of	Internet	research.	By	pointing	out	the	issue	of	data	use,	this	paper	informs	the	discussion	about	the	capacity	of	patient-powered	networks	to	support	research	participation	and	the	patient	voice.	
Keywords:	patient-powered;	orphan	diseases;	social	media;	data	openness;	patient	participation;	participatory	research.	
Social	media	and	biomedical	research	Over	the	past	few	years,	we	have	witnessed	how	web-based	digital	technologies,	social	media	and	networks	such	as	forums,	blogs,	wikis	and	sharing	sites	change	the	way	in	which	social	information	is	produced,	shared	and	accessed	(Gerlitz	and	Helmond,	2013;	Tempini,	2015;	van	Dijck,	2013).	These	institutional	and	social	changes	contribute	to	the	reconfiguring	of	the	foundations	of	the	modern	diversification	of	expertise	and	the	division	of	labour	(Callon	et	al.,	2009;	Wynne,	1996;	Del	Savio,	2015).	Especially	in	terms	of	the	web,	the	existence	of	an	increasing	number	of	organisations	that	base	their	work	processes	and	expert	services	on	the	contributions	of	a	distributed	user	base	seems	to	question	the	ways	in	which	the	relationship	between	public	and	professional	experts	has	been	structured	in	the	production,	retrieval,	interpretation	and	use	of	personal	data	(Kallinikos	and	Tempini,	2014;	Prainsack,	2014a).	Hence,	it	has	the	potential	to	reconfigure	the	roles	that	citizens	play	as	social	interaction	is	translated	through	digital	infrastructures.		One	domain	of	application	for	such	infrastructures	is	biomedical	and	health	research,	which	some	claim	they	are	pervasively	transforming	(Nielsen,	2012;	O’Connor,	2013;	Swan,	2012;	Lee	and	Cawley,	2009;	Eysenbach,	2008).	Ubiquitous	devices	for	the	collection	of	data	at	an	individual	level	(Lucivero	and	Prainsack,	2015)	and	the	emergence	of	online	health-related	services	and	data	analytics	are	seen	as	paving	the	way	for	more	precise	healthcare	and	accelerating	clinical	discovery	(Topol,	2012),	as	well	as	offering	greater	resources	to	promote	citizen	empowerment	and	autonomy	(Prainsack,	2014b;	Wyatt	et	al.,	2013a).	This	convergence	of	the	imaginaries	of	big	data,	precision	medicine	and	participation	is	a	significant	trend	in	how	contemporary	innovation	in	health	is	portrayed,	and	one	that	has	attracted	the	attention	of	policymakers	and	analysts	(Richards	et	al.,	2015;	Collins	and	Varmus,	2015).		
  
In	this	panorama,	a	set	of	social-media-based	health	research	networks	stands	out,	also	called	
patient-powered	networks;	well-known	examples	are	PatientsLikeMe	and	CureTogether.	These	enterprises	claim	to	have	the	potential	to	accelerate	medical	research	and,	at	the	same	time,	broaden	its	field	of	participation	by	opening	the	research	agenda	to	the	priorities	of	patients,	who	are	the	ultimate	recipients	of	scientific	discoveries	and	innovations.	Patients	of	chronic	conditions	have	considerable	medical	expertise,	including	experiential	knowledge	and	an	in-depth	acquaintance	with	scientific	literature;	it	is	not	surprising,	therefore,	that	online	patient	expert	groups	have	first	emerged	among	chronic	patients	(Fox	et	al.,	2005).	With	the	help	of	such	networks,	some	patient	groups	have	participated	in,	and	sometimes	initiated,	systematic	patient	experience	research.	This	has	included	off-label	self-experimentation	with	drugs	that	eventually	resulted	in	top-tier	scientific	journal	publications	(e.g.	Wicks	et	al.,	2011).	According	to	arguments	advanced	by	their	leaders	(Wicks	et	al.,	2014;	Wicks	and	Heywood,	2014),	these	networks	continue,	in	a	new	organizational	form,	a	trend	of	patient	activism	and	participation	in	research	that	started	to	emerge	well	before	the	advent	of	social	media	(e.g.	Epstein,	1996;	Feenberg	et	al.,	1996;	Rabeharisoa	and	Callon,	2002).	Patients	are	invited	to	engage	in	“data	donation”	for	the	benefit	of	others	(Ruckenstein	and	Schüll,	2017).	The	rhetoric	of	participation	purports	a	continuation	of	the	trajectory	of	radical	patient	movements	fighting	for	empowerment,	especially	in	the	case	of	‘orphan	diseases’,	conditions	(rare	or	disputed)	that	are	unable	to	mobilise	the	attention	and	investments	necessary	to	develop	effective	treatments.	This	argument	seems	to	complement	the	observed	trend	of	patient	organisations	shifting	their	attention	from	the	care	and	management	of	illnesses	to	the	active	production	of	knowledge,	a	phenomenon	that	has	been	described	as	“evidence-based	activism”	(Rabeharisoa	et	al.,	2013).	Social	observers	are	interested	in	understanding	to	what	extent	these	networks	can	deliver	on	their	promises	(Prainsack,	2014a,	2017).			We	start	from	the	basic	assumption	that	social-media-based,	patient-powered	research	networks	(health	networks	that	“funnel”	data	towards	research	purposes)	are	organised	around	the	generation,	collection,	interpretation	and	operationalisation	of	self-reported	data.	They	adopt	an	innovative	organisational	model	based	on	the	systematic	involvement	of	the	‘lay’	patient	in	the	crucial	tasks	of	observation	and	data	collection	(Kallinikos	and	Tempini,	2014).	To	understand	the	social	and	political	consequences	of	these	initiatives,	then,	one	must	‘follow	the	data’.	It	is	by	tracing	the	data	journeys	(Leonelli,	2016;	Büscher	et	al.,	2014)	that	we	can	answer	pressing	questions.	Who	gets	to	use	the	data?	For	what	use,	and	what	are	they	able	to	achieve?	
Who	decides	who	gets	access?	What	conditions	shape	the	epistemic	life	of	patient-generated	data?	If	we	want	to	seriously	consider	the	issue	of	patient-generated	data	as	epistemic	and	political	resources,	we	need	to	ask	these	kinds	of	questions.	The	conditions	shaping	what	can	be	done	with	patient-generated	data,	in	turn,	shape	how	the	patient	voice	is	expressed	(and	therefore	its	socio-scientific	value).	Critical	studies	based	on	a	critique	of	participation	as	labour	(e.g.	Cooper,	2012;	Lupton,	2013)	have	advanced	insightful	questions	of	power,	exploitation	and	value	capture	in	the	new	media	(Ruckenstein	and	Schüll,	2017),	but	what	we	want	to	pay	attention	to	here	is	whether	patient	voice	and	contributions	as	represented	in	data	are	in	fact	used	to	create	some	other	form	of	value	through	scientific	research,	or	not.	In	other	words,	if	patients	“donate”	data	for	a	cause	but	there	is	no	consequence,	we	think	this	is	worth	reflecting	upon.		The	article	argues	that	the	use	of	the	data,	for	research	or	the	expression	of	the	patient	voice,	that	participatory	health	social	media	networks	routinely	collect	is	often	constrained	–	in	ways	that	are	at	odds	with	the	ideals	of	a	sharing,	open	and	supportive	epistemic	community	that	the	
  
narratives	of	the	network	proponents	evoke.	We	will	argue	that	an	important	factor	in	conjuring	up	this	contradiction	is	the	difficulty	of	reconciling,	in	an	inclusive	data	governance	model,	of	other	heterogeneous	requirements	such	as	patient	protection	and	quality	control	and,	most	importantly,	the	principle	of	monopoly	on	data	use	that	the	business	models	of	many	Web	2.0	networks	are	centred	on.	The	high	expectations	that	the	participatory	visions	of	these	networks	elicit	risk	being	frustrated,	as	these	ventures	can	generate	new	divides.	These	divides	resemble	those	observed	in	the	health	research	economies	that	pre-dated	the	advent	of	the	web,	with	the	marginalization	of	underserved	‘orphan	disease’	communities,	yet	they	can	be	configured	differently,	along	redrawn	boundaries.	Because	of	the	dynamics	that	we	observe	to	the	economies	of	digital	health	research,	this	industry	as	well	can	generate	its	own	orphan	communities,	which	here	we	refer	to	as	the	digital	orphans.i	The	paper	is	structured	as	follows.	In	the	next	section,	we	provide	a	brief	review	of	certain	sources	in	the	broader	discussion	on	health	social	media.	We	then	touch	upon	examples	of	patient-powered	networks	that	can	be	related	to	the	concerns	of	this	paper.	We	discuss	our	overview	and	reflect	on	some	potentially	promising	scenarios	in	the	concluding	sections.	The	argument,	general	in	kind,	that	we	present	in	this	article	is	mainly	built	from	publicly	available	information,	and	from	a	review	of	scholarly	literature.	Publicly	available	information	includes	Internet	resources	(e.g.	corporate	webpages,	news	outlets)	and	case	studies	of	patient-powered	networks	published	in	peer-reviewed	journals,	including	authors’	own.	The	cases	were	selected	as	representative	examples	of	patient-powered	networks:	the	data	that	patients	share	will	be	consequentially	used	for	some	kind	of	application	(esp.	research)	that	the	networks	promise	to	pursue;	and	the	only	relationship	occurring	between	the	network-owner	organization	and	the	patient	users	is	one	based	on	data	sharing.	There	is	no	financial	transaction	or	sale	of	products	and	services	between	these	two	parties.	Instead,	the	patient-powered	networks	we	are	interested	in	are	aiming	to	be	sustainable	without	requiring	from	the	patients	anything	else	than	their	data	(and	the	effort	it	takes	to	share	them).	In	these	cases,	we	think,	the	contrast	that	we	are	highlighting	is	perhaps	starker.	Among	the	broader	group	of	suitable	cases,	we	selected	cases	for	which	information	about	their	business	model	is	available,	and	that	cover	different	areas	in	the	spectrum	of	initiatives:	the	first	two	networks	are	focused	on	consumer	feedback	services,	the	other	two	on	data-based	community	building.	We	define	them	further	in	what	follows.			
Participation	and	openness	in	social	media-based	health	networks	In	response	to	a	growing	interest	in	patient-powered	networks,	scholars	have	often	focused	on	the	issues	of	patient	protection	and	possible	harms	(due	to	unsupervised	and	risky	experiments	conducted	through	these	networks	and	a	lack	of	ethical	monitoring)	and	on	the	methodological	limitations	of	employing	patient-generated	data	(e.g.	Vayena	et	al.,	2015;	O’Connor,	2013;	Vayena	and	Tasioulas,	2013a,	2013b;	Janssens	and	Kraft,	2012;	Lee	and	Cawley,	2009).	When	issues	involving	the	control	of	data	emerge,	they	are	often	in	relation	to	possible	misuse	and	not	the	potential	conflicts	of	interests	that	can	emerge	in	these	initiatives.	Web-based	health	data	initiatives	are	frequently	supported	by	arguments	of	empowerment,	democratisation	and	citizen	participation	(Kelty	and	Panofsky,	2014).	Their	potential	lies	in	empowering	individuals	by	decreasing	reliance	on	authoritative	biomedical	professionals	in	the	generation,	access,	interpretation	and	clinical	use	of	medical	data	(Feenberg	et	al.,	1996;	Kallinikos	and	Tempini,	2014;	Prainsack,	2014b;	Rabeharisoa	et	al.,	2013;	Salter	et	al.,	2015;	Wyatt	et	al.,	2013a),	as	well	as	increasing	patient	autonomy,	especially	in	combination	with	the	emergence	of	direct-to-
  
consumer	diagnostic	services	(Alison	et	al.,	2012).	However,	it	is	important	to	pay	attention	to	potential	conflicts	among	the	actors	participating	in	these	networks	(i.e.	patients	from	different	communities,	managers	of	these	research	networks,	scientists,	investors	and	the	industry).	In	this	respect,	close	cooperation	with	the	industry	can	be	a	way	of	increasing	innovation	in	research	and	services,	through	a	faster	feedback	loop	in	healthcare.	Data	from	patient-powered	networks	have	been	used	for	investigating	comparative	effectiveness	and	quality	of	life	questions,	but	there	have	been	also	‘virtual	trials’	(Wicks	et	al.	2011).	The	transfer	of	data	from	patients	to	companies	–	data	that	can	then	be	developed	to	deliver	cutting-edge,	better-targeted	services	and	care	back	to	patients	–	can	be	mutually	advantageous.	Innovation	might	especially	benefit	research	on	‘orphan’	diseases	–	i.e.	those	diseases	excluded	from	‘standard’	research	pipelines	(Nielsen,	2012;	Sablinski,	2014;	von	Hippel,	2005).	The	existence	of	orphan	diseases	is	a	notorious	failure	of	market-based	research	structures,	and	hence	the	resolution	of	this	cul-de-sac	would	be	powerful	evidence	in	favour	of	patient-powered	research.	Besides	these	beneficial	research	scenarios,	an	active	involvement	of	patients	in	their	own	health	management	can	help	decrease	the	costs	of	healthcare	(Richards	et	al.,	2015;	Robert	et	al.,	2015).	Social-media-based	interaction	can	be	valuable	and,	by	and	large,	help	integrate	the	uneven	levels	of	care	that	patients	have	access	to	(Alison	et	al.,	2012;	Prainsack,	2014b).		The	argument	for	a	participatory	turn	enabled	by	digital	technologies	has	not	gone	unchallenged,	both	in	the	health	domain	and	elsewhere.	Authors	have	questioned	organisational	arrangements,	typical	of	the	many	crowdsourcing	models,	that	assume	free	sourcing	of	labour.	Lupton	(2013)	argues	that	the	commodification	of	“patient	opinion”	is	especially	problematic	when	not	accompanied	by	a	full	disclosure	of	financial	interests	to	the	network	members.	While	she	acknowledges	that	patients	are	now	able	to	express	their	views	and	offer	more	effective	feedback	to	care	and	research,	she	also	highlights	how	new	forms	of	exploitative	valuation	are	emerging	that	sustain	an	extractive	economy	based	on	sharing	and	‘prosumption’	(also	Bonsu	and	Darmody,	2008;	Thorpe,	2010;	Thorpe	and	Gregory,	2010).	Looking	at	the	organisation	of	drug	development	research	conducted	through	clinical	trials	and	social-media-based	networks,	Cooper	(2012)	argues	that	the	managers	of	these	social-media-based	networks	–	by	retaining	proprietary	control	on	datasets	and	accordingly	exploiting	intellectual	property	regimes	–	are	both	betraying	the	rhetoric	of	openness	that	commonly	supports	web-based	initiatives	and	exploiting	participants	as	unpaid	labourers.ii	However,	whether	social	interaction	and	data	collection	intermediated	through	social	media	technology	qualifies	as	exploited	labour	is	a	debated	issue	(Ekbia	and	Nardi,	2015;	Nardi,	2015;	Rigi	and	Prey,	2015).	The	risk	is	to	ignore	how	networks	enable	the	public	sphere	(Jin	and	Feenberg,	2015),	and	how	they	are	underscored	by	a	wider	set	of	values	(Riso	et	al.	2017).	Not	all	the	value	created	by	social	media	platforms	from	user	data	can	be	commodified	and	alienated	from	the	users	who	contribute	to	their	creation	(Tempini,	2017;	Heaton	and	Proulx,	2015).	Social	media	might	perhaps	be	understood	as	sourcing	an	organizational	function	outside	of	labour	relation.	Ekbia	(2016),	for	instance,	argues	that	labourers	in	social	media	are	the	waged	staff.		Our	argument	is	also	interested	in	the	political	economy	of	these	networks;	however,	we	take	a	different	perspective.	We	are	interested	in	asking	whether	the	effort	in	openness	that	is	required	of	patients	about	their	own	lives	(cfr.	‘shareveillance’	–	see	Birchall,	2017)iii	can	be	adequately	matched	by	an	effort	by	the	network	in	opening	data	governance	and	in	putting	the	data	to	use.	What	we	argue	is	an	interesting	vantage	point	from	which	to	consider	this	relationship:	does	the	effort	that	patients	put	in	for	the	‘datafication’	of	their	own	lives	–	for	
  
purposes	that,	among	others,	include	the	public	good	–	entitle	them	to	a	stake	in	the	data’s	onward	mobilisation	and	use	in	research?	And,	indeed,	issues	related	to	the	right	to	self-determination	already	shape	patients’	stakes	in	respect	to	how	the	data	they	share	are	used	(Aicardi	et	al.,	2016).	The	issue	we	are	drawing	on	here,	in	other	words,	is	whether	we	should	think	of	the	failure	to	make	use	of	systematic	records	of	the	patient	voice	as	a	problem;	whether	patients	should	allow	for	their	data	“donation”	to	be	left	to	no	consequence,	or	not.		In	the	world	of	social	data	and	crowdsourced	production,	the	assumption	often	seems	to	be	that	no	data	will	go	to	waste	and	that	all	data	and	user	contributions	are	productively	used.	Contrary	to	this,	we	do	not	think	that	the	reuse	of	data	happens	seamlessly,	and	we	argue	that	patient	data	are	often	not	put	to	use	as	patients	could	hope.	One	well	documented	reason	for	this	is	that	patient	data	are	difficult	to	use,	first	because	of	the	many	potential	sources	of	bias	that	can	interfere	in	the	representation	of	the	medical	situation	at	hand	(issue	of	data	quality),	and	second	because	of	the	intricacies	involved	in	successfully	resituating	data	in	new	contexts	of	use	(issues	of	documentation	and	collaboration	organization).	This	point	has	been	put	forward	regarding	data	shared	within	specialist	scientific	communities	–	for	instance,	by	Leonelli	(2016;	2014)	–	but	it	is	particularly	sensitive	in	the	case	of	distributed	data	collection	of	patient	contributions	via	social	media	(Wyatt	et	al.	2013b):	the	standards	and	practices	of	patient	recording	can	be	very	variable	yet	difficult	to	scrutinize,	making	it	very	labour-intensive	to	consolidate	the	data	in	aggregated	that	can	be	reliably	used	as	evidence	(see	Tempini,	2015;	Kallinikos	and	Tempini,	2014).		Here,	however,	we	are	suggesting	a	different	issue.	Patient-powered	networks	might	have	shortcomings	that	are	related	to	the	failure	of	market-based	approaches	to	efficiently	structure	such	networks.	The	institutional	ecology	(Star	and	Griesemer,	1989)	that	makes	up	and	surrounds	these	social-media-based	networks	shapes	the	fate	of	the	data.	Different	actors	see	data	and	their	value	differently.	As	Andrejevic	(2015)	observes,	organisations	managing	social	media	are	entirely	dependent	on	data:	control	is	key.	A	social	media	organisation	operates	within	a	broader	socio-economic	environment	to	which	it	is	tied	through	multiple	relations,	the	most	influential	of	which	are	often	those	tied	to	funding	streams.	The	strategy	chosen	to	generate	revenue	from	the	use	of	data	shapes	the	ways	in	which	the	patient	voice	is	made	valuable,	and	where	the	power	is	located	shapes	how	the	data	is	used.	The	issue	of	‘consequential	sharing’	raises	important	questions	in	the	context	of	the	sharing	economy,	where	many	patients	donate	data	(and	the	time	and	effort	involved	in	producing	that	data)	so	as	to	benefit	a	cause,	while	also	–	and	not	unimportantly	–	facing	some	risks	(for	instance,	the	consequences	of	disclosures).	We	argue	that	it	can	engender	digital	health’s	own	kind	of	market	failure,	the	digital	orphans	–	orphan	diseases	of	the	digital	research	economy.	The	circumstances	shaping	the	use	of	data	that	users	generate	might	differentiate	between	patient	groups	in	terms	of	their	chances	of	participation	and	their	contribution	to	research.	Although	all	patients	who	partake	in	these	networks	are	exposed	to	the	same	culture	of	“data	donation”	and	“openness”,	we	wonder	if	all	data	are	created	through	equal	conditions,	as	decisions	about	data	use	in	research	are	often	ultimately	taken	by	social	media	managers	who	have	to	respond	to	multiple	organisational	imperatives	and,	hence,	evaluations	of	sustainability,	growth	and	revenue	(Tempini,	2017).	The	sole	and	sheer	degree	of	diversity	across	the	patient	base	of	some	health	networks	suggests	that	it	is	extremely	difficult	to	serve	all	participants	equally,	according	to	the	ideals	of	openness,	patient	participation	and	empowerment.	How	is	it	possible	to	make	sure	that	the	data	that	patients	contribute	are	put	to	good	use	and	exploited	for	research?	The	
  
paper	points	out	difficulties	that	business	models	centred	on	data	closure,	i.e.	exercising	a	monopoly	on	the	use	of	data,	encounter	in	keeping	pace	with	the	expectations	they	raise.	The	issue	of	digital	orphans	is	one	that	requires	reflection	on	what	kinds	of	partners	come	together	for	these	networks,	and	how	their	worldviews	shape	the	circulation	and	reuse	of	data	for	the	public	good.		
Regimes	of	data	sharing	in	patient-powered	networks	Social-media-based,	patient-powered	networks	are	centred	on	both	health	data	self-reporting	and	patient	social	networking.	They	collect	large	amounts	of	structured	and	unstructured	data	on	people’s	symptoms,	comorbidities,	drug	regimes,	side	effects,	functional	changes	and	other	aspects	of	their	lives.	Patients	can	browse	the	network	through	a	web	of	profiles,	content	and	comments.	These	two	aspects	of	health	social	networks	–	i.e.	health	data	self-reporting	and	patient	social	networking	–	are	inseparable	sides	of	the	same	coin.	The	aim	is	to	activate	a	feedback	loop:	social	interaction	is	fostered	by	data,	and	data	generation	is	fostered	by	social	interaction	(Gerlitz	and	Helmond,	2013).	These	initiatives	innovate	by	easing	the	generation	and	retrieval	of	medical	information,	and	change	the	ways	in	which	information	is	collected,	assembled,	coded,	collated	and	shared	(Griffiths	et	al.,	2012).	These	social	media	features	shape	the	structure	of	incentives	for	participation	in	the	network.	Patients	sharing	data	online	are	often	motivated	by	the	hope	of	contributing	to	finding	a	cure	for	their	own	condition	or	the	condition	of	a	family	member,	even	if	they	may	not	benefit	from	it	themselves.	They	might	participate	in	medical	research	for	altruism	and	other	intrinsic	motivations	connected	to	the	ideals	of	the	scientific	enterprise.	In	addition,	they	often	hope	that	the	data	and	their	experience	may	prove	insightful	for	other	patients,	thus	furthering	the	contribution	of	their	data	beyond	a	simple	research-only	use.	Finally,	they	might	participate	to	offer	and	receive	socialisation	and	support	opportunities.	Data	generation	and	sharing	are	then	supported	by	a	diverse	array	of	technological	solutions.iv	Patients	do	not	directly	benefit	from	the	economic	value	generated	by	their	labour,	while	they	face	certain	(opportunity)	costs	when	they	invest	their	time	and	energies	in	the	collaboration.	Also,	any	other	benefit	they	might	contribute	to	–	such	as	scientific	and	care	innovation	–	is	projected	in	the	future	(Giannella,	2015).	For	their	sustainability,	they	often	pursue	one	or	more	of	a	number	of	monetisation	options,	including	selling	datasets	or	research	services	to	healthcare	corporations	(pharmaceutical	companies,	insurance	plans,	etc.),	advertising	drugs	and	products,	and	recruiting	for	clinical	trials.	Patient-powered	networks	occupy	a	niche	in	a	broader	constellation	of	initiatives	regarding	the	collection	of	patient	feedback,	opinions	and	experience	in	the	form	of	data	and	their	delivery	to	healthcare	and	research	service	providers	in	the	form	of	information	services.	Patients	are	well	positioned	to	produce	data	about	their	experiences	with	regards	to	a	number	of	health	dimensions	(e.g.	symptoms,	effects	of	drugs,	co-morbidities,	life	course	information),	in	addition	to	everyday	coping	and	support.	The	niche	is	created	by	the	possibility	of	feeding	patient-generated	data	to	research	users.	These	networks	have	diverse	combinations	of	different	types	of	institutional	nature,	stated	mission	and	legal	status;	and	revenue	strategy	and	data	governance	models.	These	conditions	shape	the	alignment	of	different	interests	and	values	on	a	network	(cfr.	Riso	et	al.,	2017),	and	set	constraints	on	the	creation	of	a	research	agenda	and	how	data	is	reused.	We	briefly	illustrate	this	using	a	few	examples	of	patient-powered	networks,	starting	with	networks	that	are	least	orientated	on	scientific	research.		
Consumer	feedback	
  
Some	networks	that	collect	patient-generated	data	provide	spaces	for	rating	and	commenting	on	the	care	and	clinical	services	and	products,	including	pharmaceuticals.	The	motivation	for	developing	and	using	these	networks	seems	to	mirror	that	of	other	feedback	networks	in	the	sharing	economy	(e.g.	Yelp!	for	rating	local	businesses	and	TripAdvisor	for	rating	hospitality	businesses).	The	model	can	be	used	to	support	healthcare	providers	in	terms	of	the	quality	of	their	services,	or	express	disappointment	if	the	service	was	deemed	inappropriate.	For	example,	Care	Opinionv,	a	UK	non-profit	network	funded	by	the	Scottish	government,	allows	patients	to	leave	feedback	about	healthcare	and	social-care	providers,	including	the	UK	National	Health	Service.	Its	initial	funding	was	provided	by	the	Scottish	government,	but	the	network	charges	health	care	services	organisations	fees	for	advanced	services	such	as	feedback	management.	The	network	aims	at	making	patient	experience	“available	as	widely	as	possible”.	On	this	basis,	review	data	can	be	browsed	and	republished	on	the	web	for	free.vi	Patient	review	data	are	automatically	forwarded	to	care	providers,	health	care	regulators,	patient	watchdogs	and	patient	organisations.	If	providers	implement	changes	based	on	patient	feedback,	they	can	publish	the	information	on	the	website	(Munro	2017).	The	full	access	to	datasets	requires	payment	of	a	fee.	Care	Opinion	also	sells	advanced	feedback	analysis	and	management	services	to	health	care	services	organisations.	Also	sourcing	patient	data	in	a	similar	way	are	networks	dedicated	to	pharmaceuticals,	often	supported	by	corporate	entities.	One	leading	case	is	MediGuard,	a	platform	collecting	patient	feedback	on	pharmaceuticalsthat	is	owned	by	the	biggest	contract	research	organisation	worldwide,	Quintiles.	Founder	Hugo	Stephenson	argued	that	Mediguard	was	created	because	“people	were	asking	the	consumer	what	they	thought	of	drug	safety”	(Barriaux	2007).	Its	2,699,000	users	learn	about	the	service	both	online	and	from	their	medical	providers,	and	join	to	provide	ratings	and	reviews.	Altough	MediGuard	warns	against	interpreting	the	information	made	available	as	medical	advice,	the	website	staff	consolidate	and	publish	risk	ratings	and	profiles	about	the	pharmaceuticals	that	patients	review.	Users	can	then	browse	the	risk	information,	along	with	reported	drug	alerts	issued	by	regulators	such	as	the	US	Food	and	Drug	Administration.	Patient	data	are	used	to	profile	patients,	both	to	improve	user	experience,	but	most	importantly	to	be	able	to	market	patients	as	audience	for	clinical	trial	enrolment	campaigns	(a	core	market	interest	of	the	parent	company	Quintiles).	Thus	data	are	shared	“with	our	clinical	research	partners	to	assist	them	in	better	designing	their	websites	and	clinical	trials”.vii	It	was	to	seize	this	original	market	proposition	and	relationship	to	patients,	that	Quintiles	purchased	the	technology	startup.		
Patient	social	networks	Another	kind	of	patient-powered	network	is	focused	on	community	building	through	the	development	of	a	social	space	where	patients	can	meet	others,	as	well	as	interact	and	learn.	Within	this	group,	Griffiths	et	al’s	(2015)	review	of	research	participation	in	health	social	networks	singles	out	two	patient-powered	social	networks	geared	towards	research-focused	utilisation	of	network	data:	CureTogether	and	PatientsLikeMe.viii	
CureTogether	CureTogether	was	set	up	to	facilitate	the	exchange	of	information	on	symptoms,	diagnoses	and	treatments	between	patients.	The	platform	was	originally	conceived	to	be	disease-specific	and	focused	on	three	pain-related	conditions	only,	but	was	soon	enlarged	upon	the	requests	of	users.	Users	of	CureTogether	describe	their	symptoms	in	disease-specific	surveys,	post	on	the	forum,	seek	and	interact	with	other	similar	users	on	the	basis	of	common	conditions	or	
  
symptoms,	and	browse	the	summary	information	curated	by	the	staff	of	CureTogether.	The	summary	information	includes	graphs	of	symptoms,	treatments,	side	effects	and	causes	for	each	condition.	Such	information	is	exclusively	aggregated	from	data	posted	online	by	users.	While	CureTogether	declares	that	it	does	not	publish	medical	findings,ix	it	claimed	–	until	late	2012	–	to	produce	“research	findings”	based	on	the	statistical	analyses	of	datasets.	In	one	case,	CureTogether	claimed	to	have	replicated	a	study	on	the	effects	of	low-dose	naltrexone	on	fibromyalgia	patients.x	The	platform’s	orientation	towards	research	is	also	suggested	(in	a	witty	manner)	by	its	claim	that	the	website	would	have	been	called	“Patient-driven	research”	if	it	were	not	for	the	long	URL.xi	The	mission	statement	explicitly	endorses	this	claim:	“Partnering	with	universities,	research	organizations,	and	self-experimenters	will	help	us	to	make	new	discoveries	and	connections	faster,	ask	better	questions	about	patient	data,	and	validate	that	online	methods	for	data	gathering	are	effective	for	research	purposes.”xii	The	data	are	however	a	proprietary	asset	of	the	company:	the	exploitation	in	research	is	dependent	on	their	financial	evaluation.	Armstrong	et	al.	(2012)	evaluated	the	reliability	of	CureTogether’s	crowdsourced	data	focused	on	a	specific	condition	–	the	skin	disease,	rosacea	–	and	concluded	that	“crowdsourcing	has	the	potential	to	yield	high-volume	data	from	diverse	patient	populations”	but	that	chief	limitations	include	“low	number	of	responses,	unspecified	medication	diagnoses	and	duration,	and	unknown	adherence	rates”	(2012:15).	They	also	emphasised	the	differences	between	outcome	measures	in	crowdsourcing	sites	and	traditional	clinical	trials	that	prevent	accurate	comparisons.xiii		CureTogether	and	its	four	million	phenotypic	data	points	were	eventually	acquired	by	a	personal	genomics	company,	23&Me,	in	July	2012	in	an	explicit	effort	to	combine	23&Me’s	large	genomic	databases	with	epidemiological	and	phenotypic	data.	Today,	CureTogether	has	a	user	base	of	ca.	39,000	people	collecting	data	on	about	637	conditions.xiv	After	the	acquisition,	CureTogether’s	operations	were	integrated	with	23&Me.	Infographics	based	on	the	datasets	have	been	published	on	23&Me’s	websitexv	in	a	page	reporting	an	overview	of	each	pairwise	significant	association	between	CureTogether	users’	medical	conditions.	While	the	website	still	runs,	there	have	been	very	few	updates	of	the	blog,	its	research	sections	and	the	live	feeds.	The	utilization	of	the	data	in	research	now	depends	on	the	alignment	with	23&Me’s	strategic	interests.	The	business	model	of	23&Me	includes	the	sale	of	genomic	and	ancestry	personal	testing,	collaboration	with	the	industry	for	medical	R&D	based	on	users’	genomic	and	self-reported	data,	and,	eventually,	earning	royalties	from	patented	discoveries	(see	Harris	et	al.,	2016).	
PatientsLikeMe	PatientsLikeMe	is	one	of	the	most	popular	social-media-based	health	research	network.	The	way	patient	contributions	and	data	generation	and	consumption	activities	are	organized	has	already	been	well	documented	(Tempini	2015,	2017;	Kallinikos	and	Tempini,	2014).	We	will	refer	here	to	those	resources	but	for	essential	introduction	and	some	key	remarks	related	to	the	concern	of	this	paper	with	business	models	and	data	governance.xvi	Through	the	site,	patients	can	connect	to	other	patients,	keep	a	log	of	their	health	history,	and	participate	in	medical	research	that	the	research	team	of	the	organisation	conducts	and	publishes	in	peer-reviewed	journals	and	other	outlets.	Data	collection	involves	a	number	of	health-relevant	dimensions:	conditions,	treatments,	symptoms,	quality	of	life,	hospitalisations,	lab	results,	weight,	and	disease-specific	patient-reported	outcome	measures	(PROMs).	This	for-profit,	ad-free	network	is	sustained	through	funding	from	partnerships,	mainly	with	the	pharmaceutical	industry,	
  
centred	on	the	sharing	of	pseudonymised	data	and	the	execution	of	custom	research.	Patient	involvement	in	research	is	limited	to	the	collection	of	data	and	the	opportunity	to	collaborate	in	the	development	of	interfaces	and	tracking	tools.	However,	the	organisation	simply	would	not	be	able	to	run	without	the	continuous	collaboration	with	its	patient	members;	and	patients	are	not	bound	to	participation	by	any	kind	of	contract,	are	physically	distributed	all	over	the	planet	and	are	extremely	diverse	not	only	due	to	the	kinds	of	patient	experiences	they	are	going	through,	but	also	due	to	the	kinds	of	literacy	they	mobilise	to	make	sense	of	it.	After	a	long	undertaking	to	restructure	the	network’s	architecture,	in	2011	PatientsLikeMe	became	a	unique	social	network	that	could	connect	all	patients	of	all	conditions	together	(Tempini,	2017).xvii	It	was	not	a	painless	transformation:	due	to	the	incompatibility	of	the	new	data	architecture	with	data	that	patients	had	previously	collected	about	their	co-morbidities,	the	implementation	necessitated	the	removal	of	some	of	the	old	data	from	the	website,	to	be	‘parked’	for	good	(Tempini,	2014)	–	an	example	of	the	kinds	of	uneasy	data	governance	trade-offs	that	patient-powered	networks	needs	to	face	in	their	day-to-day	management.	Importantly,	PatientsLikeMe’s	new	architecture	allowed	patients	of	any	given	condition	to	join	the	network	before,	instead	of	after,	any	research	activity	on	a	given	condition	had	been	conceived.	Rather	than	launching	a	community	as	a	consequence	of	starting	a	research	project,	it	made	it	possible	to	conceive	of	research	because	determinate	patient	groups	aggregated	on	the	network.	However,	the	onward	sharing	and	use	of	data	in	research	would	need	to	wait	for	a	new	project	–	funded	by	a	partnership	–	that	allowed	R&D	efforts	to	begin.	While	the	number	of	hosted	conditions	exploded	with	the	new	architecture	from	ca.	25	to	more	than	1,400	in	the	first	year	alone,	as	did	the	number	of	patient	members,	their	data	were	still	scarcely	used	in	any	research	activity	unless	a	funded	project	had	been	started	that	allowed	data	to	be	generated	and	worked	with	according	to	the	standards	and	processes	that	medical	research	requires.	The	research	staff’s	deeper	experience	in	the	study	of	neurodegenerative	diseases	meant	that,	even	years	later,	a	great	amount	of	the	studies	generated	from	PatientsLikeMe	data	focused	only	on	diseases	such	as	Amyotrophic	Lateral	Sclerosis,	Multiple	Sclerosis	and	Parkinson’s	Disease.	While	the	company	made	available	its	web	tools	to	patient	communities	of	all	kinds	of	diseases,	and	the	it	was	able	to	develop	its	research	capabilities	further,	patient	‘data	donations’	became	more	uncertain,	overall,	to	be	used	in	research.	The	network	has	grown	further,	launching	the	Open	Research	Exchange,	a	system	that	allows	more	systematic	involvement	of	patients	in	the	design	and	development	and	use	of	Patient-reported	Outcome	Measures	(PROMs),	with	the	aim	to	accelerate	the	development	process	and	to	design	tools	that	are	closer	to	the	patient	experience	and	thus	more	meaningful	for	end	users.	The	pre-existing	data	governance	arrangement	subsists;	the	organisation	controls	access	to	patient	data	because	its	business	model	is	centred	around	its	proprietary	exploitation.		
Digital	economy,	digital	orphans?	The	aim	of	this	brief	overview	is	to	illustrate	how	the	use	in	research	of	data	from	health	social	media	is	constrained	by	business	models	and	the	institutional	ecology	that	they	support	and	are	embedded	in.	On	the	one	hand,	patient-powered	networks	are	seen	as	complementary	to	the	vision	of	a	sharing	and	supportive	society,	echoing	the	ideals	of	a	commons-based	community	and	bottom-up	research	and	empowerment.	On	the	other	hand,	they	are	developed	on	a	for-profit	basis	for	faster	development	and	market	share.	Their	key	challenge	is	to	integrate	the	high	expectations	evoked	by	a	participatory	vision	with	the	business	imperatives	of	for-profit	environments.	As	Prainsack	argues	(2017:120),	the	issue	in	this	kind	of	convergence	is	not	the	
  
convergence	of	for-profit	and	not-for-profit	elements	per	se:	the	question	is	rather	who	benefits,	and	who	is	in	charge.	Such	tensions	do	not	undermine	the	viability	of	these	networks	and	their	potential	for	scientific	innovation.	In	this	respect,	we	wonder	if,	in	the	future,	there	could	be	more	innovation	in	terms	of	organisational	forms	that	more	directly	address	the	issue	of	data	governance	and	the	democratization	of	the	reuse	of	data	that	we	have	been	trying	to	delineate.	While	the	for-profit	model	can	be	advantageous	for	accelerating	the	growth	of	these	networks,	we	suspect	that	tight	coupling	between	control	over	data	(power	over	the	research	agenda)	and	control	over	the	infrastructure	of	participation	(power	over	technology	and	community	development)	is	the	core	of	the	issue	at	stake	here.	Decisions	regarding	the	research	uses	of	patient	data	are	assigned	to	the	new	gatekeepers,	i.e.	network	developers,	who	need	to	justify	action	against	organisational	imperatives	that	are	related	to	business	partnerships	with	clients,	the	research	interests	of	participating	researchers	and	their	respective	areas	of	expertise,	and	the	perception	of	the	opportunity	for	an	impactful	contribution	(cfr.	Riso	et	al.,	2017).	It	must	be	noted	that	the	problem	might	be	compounded	by	other	reasons	to	favour	some	form	of	control	over	access	to	patient	data,	relating	to	issues	of	data	quality,	and	of	documentation	and	organization	of	collaborations.	Patient	data	can	fluctuate	widely	in	quality	and	reliability,	as	patients	can	operate	with	very	different	combinations	of	epistemic	standards,	background	knowledge,	and	motivations.	It	is	labour-intensive	to	make	available	these	data	to	different	actors	in	a	form	that	can	be	reliably	used	as	evidence.	Wyatt	and	colleagues	(2013b)	also	highlight	the	careful	juggling	act	of	data	managers	as	they	need	to	foster	trust	in	the	scientific	enterprise	from	both	patients,	investors	and	the	scientific	community.	A	great	amount	of	curation	and	interpretation	is	necessary	to	make	the	vast	amounts	of	data	valuable	for	certain	uses,	and	trusted	by	their	audiences.	The	overall	population	sample	has	its	own	peculiar	biases	(in	the	health-related	Internet,	it	is	often	white,	female,	educated,	etc.,	but	can	fluctuate)	(boyd	and	Crawford,	2012),	and	the	deep	familiarity	that	specialists	can	develop	with	data	is	key	to	making	the	data	reusable	(Fleming	et	al.,	2017).	The	expertise	of	specialists	is	crucial	to	document	the	data,	including	the	application	of	standardized	metadata.	Successful	and	repeatable	reuse	of	data	depends	on	them	to	know	the	data	in-depth	and	intermediate	with	those	other	users	that	access	the	data	for	the	occasional	research	project;	who	can	help	and	guarantee	the	quality	of	research,	controlling	for	biases	as	well	as	blatant	misuse.	If	access	is	uncontrolled,	misuse	that	could	harm	both	patients	and	the	legitimacy	of	patient	self-reported	research,	and	which	could	originate	from	many	actors,	including	both	internal	patient	members	and	external	members	of	the	public	and	organisations.		The	development	of	this	human	resource	is	an	expensive	undertaking	and	yet,	somewhat	ironically,	it	might	not	suffice	to	control	for	the	most	radical	risks	that	derive	from	self-report,	self-select	Internet	data,	that	is,	intentional	misinformation.	A	controversy	opened	when	the	BBC	reported	how	staff	of	a	healthcare	trust	in	the	UK	submitted	most	of	the	patient	reviews	about	the	trust	itself	that	were	available	on	Care	Opinion.xviii	CureTogether’s	model	of	allowing	users	to	submit	anonymous	data	on	pharmaceuticals	and	other	treatment	options	seems	also	vulnerable	to	targeted	manipulation.	But	as	nearly	any	social	media	service	on	the	Internet,	none	of	the	four	examples	we	reviewed	here	require	any	‘hard’	proof	of	identity.	As	the	general	public	has	reckoned	with	in	numerous	ways	over	the	last	few	years,	of	concern	is	not	the	lone	act	but	also	the	possibility	of	organized,	focused	actions	of	misinformation.	The	most	incendiary	debate	is	over	Russia’s	manipulation	of	the	public	sphere	over	Facebook.	But	the	fakes	industry	is	an	underwater	sector	of	the	web:	fake	product	reviews,	fake	followers,	etc.	have	been	well	
  
documented.	In	regard	to	security	and	patient	protection	as	well,	it	is	not	fully	clear	that	centralized	control	of	the	data	is	necessary	or	advisable.xix	Openness	can	elicit	broad	and	diverse	scrutiny	and	reporting.		Despite	these	obligatory	considerations,	our	argument	is	not	directly	concerned	with	the	validity	of	the	model	(at	least	not	directly)	of	knowledge	production	through	patient-powered	networks,	but	it	does	reflect	instead	on	its	magnitude.	We	wonder	if	contemporary	examples	of	social-media-based	participatory	research	really	afford	hope	for	the	kind	of	disruptive	change	that	can	shift	the	orientations	of	an	industry.	PatientsLikeMe	has	produced	a	considerable	amount	of	research,	but	it	is	the	only	example,	in	our	set,	to	systematically	achieve	this.	Still,	what	is	of	concern	is	not	so	much	the	character	of	the	research	that	is	actually	done	than	the	research	that	is	not	done	–	the	missed	opportunities	that	cannot	be	explored	due	to	the	existing	regimes	of	data	sharing.	Not	all	data	are	created	equal.	Scientifically	valuable	venues	of	research	might	be	turned	down	in	cases	where	no	industrial	interest	supports	them.	In	the	absence	of	such	interest,	the	opportunity	to	make	use	of	patient	data	remains	quite	small.	The	problem	that	scientific	research	data	too	easily	‘go	to	waste’	has	been	well	documented	(Leonelli,	2013).		The	imperatives	of	for-profit	business	models	based	on	the	monetisation	of	data	–	as	well	as	driving	research	strategies	and	monopolist	decisions	regarding	the	use	of	the	data	collected	through	these	patient-powered	networks	–	define	constraints	that	shape	the	collaboration’s	infrastructure	and	outcomes.	The	cost	in	trying	to	mediate	a	marriage	of	patient	and	industry	interests	is	to	never	(disruptively)	exceed,	in	the	use	of	the	data,	what	the	wider	institutional	ecology	of	commercial	and	research	partners	is	willing	to	engage	in.	Contrary	to	the	hypothesis	of	these	networks	functioning	as	the	centre	of	evidence-based	activism	(Rabeharisoa	et	al.,	2013)	with	patients	in	control	of	the	research	agenda	for	data	reuse,	there	is	a	risk	here	that	much	of	the	patient	input	will	never	be	used	further	than	for	fuelling	the	web-based	computational	infrastructures	that	support	online	community	interaction.	While	pre-emptive	data	collection	might	be	to	some	level	‘use-agnostic’,	business	models	are	not	(Aaltonen	and	Tempini,	2014).	Much	of	data	sharing	or	“donation”	could	have	no	consequence	in	research.		Our	review	suggests	that	not	all	web-based	participatory	research	activities	have	an	equal	chance	if	the	data	shared	by	patients	from	certain	condition	communities	are	more	intensively	used	than	other	data.	The	scenario	is	one	where	the	disruptive,	innovative	web	economy	can	produce	its	own	kind	of	market	failures.	Even	in	the	highly	inclusive	environment	of	patient-powered	research	networks,	a	patient	community	can	become	an	‘orphan’.	In	the	context	of	the	web	networks,	it	seems	that	the	problem	of	orphan	diseases	might	persist	in	a	new	form	–	notably,	to	be	eventually	shifted	between	different	disease	communities.	On	the	one	hand,	web	networks	are	potentially	helping	some	‘traditional’	orphan	patient	communities	to	increase	research	activity	around	their	causes	(for	instance,	ALS	is	the	most	striking	example	of	successful	mobilisation	through	PatientsLikeMe).	On	the	other	hand,	the	new	convergence	of	actors	in	these	digital	environments	makes	what	one	might	call	digital	orphans	of	those	diseases	(which	might	not	have	been	orphans	before	the	Internet)	that,	relative	to	patient-powered	research,	now	do	not	enjoy	the	convergence	needed	to	make	the	digital	scientific	enterprise	work.		In	the	observed	examples,	we	can	think	of	at	least	four	main	factors	that	make	such	a	convergence	possible.	First,	the	level	of	“engagement”	among	the	patient	population	can	vary	enormously	(size,	data-productive	levels	of	activity).	Second,	the	expertise	of	staff	matters,	as	
  
staff	specialise	in	certain	medical	phenomena	more	than	others,	and	are	as	a	result	differently	able	to	seize	opportunities.	Third,	the	character	and	epistemological	status	of	the	patient	experience	and	how	trustworthy	its	measurements	are	considered	to	be	affects	how	much	self-reported	patient	observations	are	trusted	beyond	the	patient	group	itself.	Fourth,	and	drawing	on	the	previous	three	points,	the	eventual	presence	of	an	industrial	interest	is	needed	to	materialise	a	research	project	by	providing	funding.	These	networks,	despite	being	continually	improved	and	built	upon	to	include	more	participants,	seem	to	have	to	necessarily	differentiate	between	patients	so	as	to	initiate,	participate	and	contribute	to	research.	This	is	no	small	consequence	and	suggests	that,	even	on	the	web,	participation	by	patients	is	a	necessary,	but	not	sufficient,	condition	to	foster	research	regarding	a	disease.	It	makes	one	challenge	the	idea	that	patients	(or	citizens)	are	‘in	charge’.		It	must	be	noted	that	probably	the	most	acclaimed	research	achievement	of	patient-powered	research	networks	–	a	PatientsLikeMe-authored	study	of	the	drug	lithium-carbonate	published	in	Nature	Biotechnology	(Wicks	et	al.,	2011)	–	was	indeed	made	possible	only	through	the	involvement	of	research	scientists	on	a	long	labour-intensive	project	(still	shorter	than	a	traditional	trial),	although	patients	had	arguably	initiated	the	research	and	made	the	opportunity	possible.	Patients	are	undeniably	important	actors	in	such	research,	but	published	research	from	web	networks,	in	most	instances,	is	not	completed	or	co-authored	by	patients	‘in	the	wild’.	While	we	agree	that	web-based	networks	are	making	it	easier	for	“patient-led	research”	and	other	disruptive	initiatives	to	happen	(e.g.	Vayena	et	al.,	2015;	Vayena	and	Tasioulas,	2013a,	2013b),	we	believe	that	the	kind	of	innovation	that	these	networks	are	driving	is	better	captured	by	the	PatientsLikeMe	staff’s	own	use	of	the	language	of	“patient-powered”	research	or	networks.	It	tracks	the	organisational	reality	more	closely,	also	conceding	to	the	potential	exclusion	of	patients	from	key	roles.	In	our	view,	the	term	“patient-led”	instead	risks	concealing	any	divergence	between	users’	and	network	managers’	interests,	and	makes	us	forget	about	the	network	development	work	that	happens	at	the	backstage	of	the	web	(see	Ekbia,	2016;	Tempini,	2015).		
Towards	open	patient-powered	research	If	we	consider	web-based	participatory	networks	as	infrastructures	for	distributed	research,	then	the	question	of	control	regarding	access	and	the	use	of	the	data	is	key.	It	must	be	noted	that	the	constraints	put	on	data	sharing	and	reuse	in	these	networks	are	linked	to	a	more	general	problem	that	besets	any	form	of	production	and	the	sharing	of	common	goods,	of	which	data	is	a	paradigmatic	example	(Eschenfelder	and	Shankar,	2016).xx	There	is	a	tension	between	the	cost	to	maintain,	develop	and	run	platforms,	and	the	fact	that	data	could	often	be	made	non-rivalrous	in	use.	Also,	a	completely	distributed	data	governance	framework,	where	every	data	donor	is	in	charge	of	the	micro-management	of	the	use	of	their	data	by	others,	arguably	offloads	on	the	individual	risks	and	trade-offs	that	are	very	difficult	to	evaluate	individually	(Aicardi	et	al.,	2016;	Evans,	2017).	Maintaining	that	making	patient	data	available	to	just	about	anyone	would	be	much	worse	(just	the	privacy	concerns	are	enough	issues	to	consider),	we	wonder	whether	it	would	be	more	beneficial	if	networks	separated	the	management	and	development	of	the	web	infrastructure	from	decisions	about	the	use	of	data	for	research	purposes.	If	this	were	organisationally	sustainable,	it	could	be	the	first	step	for	patient-powered	research	networks	to	more	fully	espouse	openness	at	both	layers:	to	match	the	openness	with	which	patients	share	details	about	
  
their	lives	with	an	openness	about	the	research	avenues	and	data	reuse	opportunities	that	the	network	would	be	able	to	support.	This	could	allow	patient-powered	networks	to	better	adopt	the	ideal	of	patients	engaging	in	“evidence-based	activism”	and	contributing	from	within	to	the	“collective	inquiry	associating	patient/activists	and	specialists/professionals	in	the	conjoint	fabrics	of	scientific	statements	and	political	claims”	(Rabeharisoa	et	al.,	2013:2).	Forms	of	federated,	hybrid	partnerships	where	trusted	patient-activist	groups	are	delegated	powers	over	data	governance	might	be	able	to	improve	oversight	and	multiply	research	projects	while	protecting	the	patients’	interests	(Vayena	and	Blasimme,	2017).	We	are	very	aware	that	the	representativeness	of	patient	groups	is	often	questioned.	Patient-activist	NGOs	have	been	criticised	for	biased	representation.	Still,	this	might	be	an	improvement	over	the	data	governance	models	that	are	common	to	the	networks	we	have	surveyed	as	examples.	To	address	this	conundrum	at	least	in	part,	some	novel	arrangements	are	being	experimented	with	to	distribute	management	over	data	use	for	data	producers	(i.e.	patients).	Patients	are	then	endowed	with	a	larger	latitude	of	control	over	what	is	done	with	their	data.	One	promising	example	of	emerging	initiatives	is	“data	cooperatives”	(Hafen	et	al.,	2014;	Riso	et	al.,	2017).	Data	cooperatives	are	organisations,	owned	collectively,	that	are	delegated	the	day-to-day	management	of	the	data	of	their	constituents,	including	data	management	tasks	and	information	governance	decisions.	They	are	fiduciaries	of	their	members’	data.	Data	cooperatives	can	be	set	up	at	varying	levels	of	locality,	and	can	refer	to	different	kinds	of	constituency	criteria.	The	data	cooperative	infrastructure	is	developed	with	the	aim	of	allowing	patients	to	upload	their	health	records,	share	them	with	others,	and	make	them	available	for	research	for	those	projects	they	find	worthy,	and	thus	tries	to	strike	a	balance	between	granular	control	and	day-to-day	delegation	to	representatives.	Their	rationale	is	to	simultaneously	tackle	two	interconnected	issues	of	data	reuse	–	namely,	inefficient	data	sharing	and	a	lack	of	distributed	decision-making:	“Inaccessibility	of	data	is	not	only	a	cause	of	inefficiency	and	increased	costs	in	the	healthcare	system,	it	also	prevents	the	citizens	to	control	their	data	and	thus	engage	more	actively	in	their	own	health”	(Hafen	et	al.,	2014:82).	The	model	aims	to	be	self-sustainable,	creating	revenue	by	charging	access	fees	to	research	users	while	keeping	the	control	over	data	governance	with	the	patients,	who	are	likely	to	be	more	interested	in	multiplying	and	diversifying	the	research	uses	of	their	data.	Interestingly,	the	chosen	policy	of	sustaining	development	through	cost	recovery	fees	is	an	ad	hoc	solution	(it	is	not	prerogative	of	cooperative	organisations)	and	may	be	experimented	with	by	other	forms	of	organisations	as	well.	Other	current	medical	research	governance	experiments	are	aimed	at	transferring	control	of	data	reuse	to	patients	without	overly	tinkering	with	data	ownership	policies.	The	US-based	Patient-Centered	Outcomes	Research	Institute	(PCORI),	a	non-profit	and	non-governmental	organisation	created	as	part	of	the	Patient	Protection	and	Affordable	Care	Act,	involves	patients	as	co-investigators	in	comparative	effectiveness	research	(Robbins	et	al.,	2016).	According	to	online	documentation,	proposals	can	be	submitted	by	patients,	caregivers,	clinicians	and	other	healthcare	stakeholders,	and	are	subsequently	reviewed	to	identify	and	prioritise	significant	topics.	Funding	applications	are	reviewed	by	professionals	and	lay	citizens.	Any	stakeholder	can	provide	commentaries	on	reports,	proposed	policies	and	other	initiatives,	and	join	the	organisation’s	advisory	panel.xxi	An	evaluation	of	50	pilot	projects	has	been	published,	showing	that	non-professional	stakeholders	were	mostly	engaged	in	topic	solicitation,	question	development,	study	design	and	data	collection	(Forsythe	et	al.,	2016),	a	result	that	suggests	that	
  
patients	can	actively	contribute	to	increase	the	opportunities	of	patient	data	reuse.	While	PCORI	does	not	govern	medical	datasets,	it	has	overlapping	aims	with	the	Open	Research	Exchange	initiative	at	PatientsLikeMe.	However,	the	PCORI	funding	arrangement	seemingly	makes	it	unconstrained	by	profitability	requirements.	While	PCORI	is	a	private	organisation,	not	a	federal	agency,	it	does	receive	public	funding	to	fulfil	its	explicit	mandate	of	collecting,	evaluating	and	expanding	citizens’	inputs	in	medical	research.	The	future	outcomes	of	PCORI	and	similar	initiatives	are	a	second	source	of	potentially	valuable	insights	to	address	the	tension	between	the	aspiration	of	patient	control	on	research,	and	its	implementation.	
Conclusions	The	emphasis	of	our	paper	on	the	conditions	in	which	patient	data	can	be	“donated”	by	patients	and	yet	left	unutilised	helps	to	highlight	an	issue	that	seems	to	characterise	web-based	infrastructures,	where	a	certain	kind	of	data-intensive	business	model	is	combined	with	a	participatory	organisational	arrangement.	How	more	open	governance	structures	like	the	ones	we	briefly	touched	upon	will	fare	remains	to	be	seen,	but	they	provide	alternative	models	to	compare	and	discuss.	Of	course,	we	are	wary	about	the	enormous	uncertainties	that	come	with	pioneering	these	models.	Development	is	costly,	ventures	can	be	difficult	to	scale,	and	the	venture	can	suddenly	need	to	respond	to	emerging	problems	that	are	specific	to	distributed	patient	engagement	and	need	to	be	addressed	contingently	through	labour-intensive	strategies	(Tempini,	2015).	We	do	not	intend	to	downplay	the	costs	and	risks	of	running	a	patient-powered	research	enterprise	through	a	different	business	model.	However,	we	welcome	more	experimentation	to	explore	how	the	development	of	such	networks	could	be	sustained	through	alternative,	more	consequential	models.	The	implications	of	online	and	digital	intermediation	are	deep	and	subtle	(Bowker,	2013)	and,	as	such,	technology	development	needs	to	allow	for	rethinking	and	re-evaluation	(Wajcman,	2015).	
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